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Background: The tumor microenvironment plays an important
role in the progression of cancer and may be regulated by prote-
olysis, including the proteasomes. The proteasomes modify the
biologically important molecules involved in the pathogenesis
and progression of a variety of malignancies, including breast
cancer (BC). The aim of this study was to investigate the features
of the subunit composition of proteasomes in the tumor and its
microenvironment of breast cancer.
Material and Methods: Thematerial for investigation was sam-
ples of tumor tissue of invasive ductal breast cancer. The study
was conducted to estimate the distribution of the total pool of
proteasome, proteasomes activator PA700, immune proteasome
forms containing LMP7 and/or LMP2 subunit in tumor cells and
stromal component using immunofluorescence. Furthermore,
there was evaluated the distribution of the proteasome in the
tumor. The expression of immune proteasomes and proteasomes
activators in the cells was studied by immunofluorescence label-
ing of the cells by antibodies to immune proteasome subunits and
cell markers. Fluorescence was analyzed by using a fluorescence
microscope DM RXA2 (‘‘Leica”, Germany) and confocal micro-
scope TCS SP (‘‘Leica”, Germany). The specificity of the primary
antibodies was confirmed by check samples, at which the
reaction was carried out only with the second antibody. No cross
reaction between the first and second antibodies was tested by
incubation of each primary antibodies with the opposing second
antibodies. In addition, there was carried out labeling the cell
nuclei by reagent Hoechst 33,342.
Results: It was found that the tumor cells comprise immune
proteasomes, also PA700 and PA28ab activators. Activator PA28ab
and immune proteasomes are localized in the cytoplasm of tumor
cells, whereas a1, 2, 3, 5, 6, 7 subunits and PA700 activator
detected in the cytoplasm and in the nuclei of tumor cells. Avail-
ability of a1, 2, 3, 5, 6, 7 subunits in the nuclei of tumor cells shows
the expression of constitutive proteasome subunits. Stromal cells
are characterized by a high ratio of the a1, 2, 3, 5, 6, 7 subunits to
the immune LMP2 subunit as compared to cells of invasive ductal
carcinoma. This means that the pool of proteasome in tumor cells
of invasive ductal cancer is enriched by the immune proteasomes
as compared to stromal cells. Thus, samples of invasive ductal
breast cancer contain predominantly tumor cells enriched by
immune proteasomes, activators PA700 and PA28ab. The presence
of proteasomes in stromal component indicates that the tumor
microenvironment also has active processes of proteolysis, with
involving proteasome system. Probably the processes occurring
in the stromal component contribute to the output of the
proteasome into the extracellular space, which is confirmed by
other researchers about the existence of circulating proteasome
pools and their further participation in dissemination of cancer.
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Background: Metformin is a antidiabetic drug with anticancer
properties. However, the mechanism action by which metformin
affects various cancer cells still unknown. It is known that tumor
growth is accompanied by changes in the metabolic cascade that
includes overproduction of lactate and adenosine. The adenosine
is released into the extracellular environment and regulates
differentiation, proliferation, and angiogenesis of tumor mass.
We found that lactate is activator of key enzyme of adenosine
metabolism – adenosine deaminase (ADA).
Aim: The aim of our study was to investigate the catabolism of
adenosine in the tumor while taking metformin.
Materials and methods: In this study we investigated the level
of adenosine, inosine, hypoxanthine and ADA activity in 15
women aged 46–76 years, with breast cancer (BC) T2-4N1M0 (can-
cer tissues) during treatment with metformin, 1000 mg per day
for 3 months. Control group – 15 women aged 46–76 years, with
stage T2-4N1M0 breast cancer (cancer tissues) without metformin
therapy.
Statistical analysis was performed using the license package
StatSoft. Statistica 12.0.
Results: ADA activity during treatment with metformin was 2-
fold increased: 12.1 ± 2.49 nmol/min*mg in comparison with 4.77
± 0.943 nmol/min*mg. Concentration of catabolic products of ade-
nosine degradation was increased before metformin therapy. Ino-
sine level was 0.121 ± 0.041 micro mol/g tissue (BC tissues from
women without metformin 0.042 ± 0.015 micro mol/g tissue).
Hypoxanthine 2.45 ± 0.428 micro mol/g tissue (in comparison
with 0.711 ± 0.269 micro mol/g tissue). Whereas, adenosine level
in BC after metformin therapy was 0.226 ± 0.148 micro mol/g tis-
sue (in comparison with 0.186 ± 0.056 micro mol/g tissue), that
were not significantly different.
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Conclusion: Thus, we have found that metformin significantly
increases the rate of catabolism of adenosine, and this in turn
reduces the inhibitory effect on the tumor microenvironment
cytotoxic cells. Therefore, our data for the first time provide novel
evidence for a mechanism that the anticancer activities of met-
formin are due to adenosine metabolism regulation.
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Background: Human epidermal growth factor receptor-2
(HER2/nue) is overexpressed in breast cancer. It has been shown
that HER2-targeted therapies have radically changed the outcome
of HER2-positive breast cancer patients. The aim of this study was
to develop the technique for preparation of recombinant anti-
HER2/neu antibody from plants and to provide with the basic
characteristics of the HER2/neu oncoprotein.
Materials and Methods: We have designed and synthesized
viral vectors to transform Agrobacterium tumifaciens affinity,
ion exchange and gel filtration chromatography were used to pur-
ify the antibody. The quality of the substance was confirmed by
SDS–PAGE and ELISA. The biological activity was tested by
immunofluorescent analysis.
Results: Antibodies were purified by affinity and ion
exchange chromatography from the Agrobacterium tumifaciens
leaves extracts. Gel filtration chromatography was used for
final purification of the protein. Immunocytochemical staining
was performed to test the functional activity of the plant-
made antibodies. Here we also show that plant-made antibod-
ies bind to HER2/neu receptors on the surface of human
SK-BR-3 breast cancer cells as effectively as the diagnostic
antibody A0485 (DAKO, Denmark). Flow cytometry analysis
was used for quantitative estimation of recombinant anti-
HER2/neu antibodies: from 75.7% to 98.3% cells bound the
plant-made antibodies. The same data were obtained with
trastuzumab.
Conclusion: Based on the data obtained, we conclude that
plant-made antibodies inhibit HER2/neu+ breast cancer cell pro-
liferation. Additional experiments are required to prove that tras-
tuzumab and plant-made antibodies share full identity in their
biological activity.
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Papillary thyroid cancer (PTC) is the most common malig-
nancy of the endocrine system. The most frequent genetic alter-
ation in PTC is the BRAF V600E mutation, which affects the
activation of several intracellular signaling pathways. As a result,
changes in the expression levels of cell membrane integrin
receptors and their ligands – extracellular matrix proteins – osteo-
pontin (OPN) and thrombospondin -1 (TSP1) are observed. This
process increases the metastatic potential of tumor cells. Thus,
integrin receptors and their ligands are potential biomarkers of
an aggressive PTC phenotype.
The aim of our study was to compare the gene expression pro-
file of integrins ITGA2, ITGA3, ITGAV, ITGA6, ITGA9, ITGB1, ITGB3
and their ligands OPNa, OPNb, and TSP1 in PTC with different
BRAF V600E mutation status.
Intraoperative thyroid tissue samples from 41 patients diag-
nosed with PTC (n = 26), diffuse nodular nontoxic goiter (n = 10)
and follicular adenoma (n = 5) were analyzed to evaluate the
expression levels of the investigated genes by real time RT-PCR.
Fluorescent immunohistochemistry (IHC) was used to confirm
the PCR results and to estimate the amount of protein products.
For IHC, frozen and paraffin sections were used. The BRAF
V600E mutation was determined using allele-specific amplifica-
tion. Nonparametric criteria (Kruskal Wallis, Wilcoxon and
Mann–Whitney tests) were used to evaluate group differences. P
values of less than 0.05 were considered statistically significant.
The BRAF V600E mutation was observed in 12 PTC samples,
which corresponds to 46% of PTC cases. An increase of gene
expression level of ITGA3 (2.9-fold, p = 0.014), ITGAV (1.9-fold,
p = 0.038), ITGB1 (1.7-fold, p = 0.026), OPNb (2.5-fold, p = 0.0001)
and TSP1 (3.2-fold, p = 0.017) was identified in the PTC tissues,
and a high gene expression level of OPNb (5.9-fold, p = 0.003)
and TSP1 (12.1-fold, p = 0.005) was identified in the tissue samples
of lymph node metastases compared to the conventionally
normal tissue.
In the samples with advanced cancer (T3, T4, TNM) the
expression levels of ITGA3, ITGA6 and ITGA9 were higher com-
pared to the T1 samples. MRNA levels of ITGA3 and ITGAV were
significantly higher in the PTC BRAF V600E positive samples than
in the BRAF V600E negative samples.
Elevated levels of OPNa (11.4-fold, p = 0.0112), OPNb (10.2-fold,
p = 0.0216) and TSP1 (33.5-fold, p = 0.0005) genes were observed in
the follicular adenoma samples compared to the PTC tissues. For
ITGA2 and ITGB3 there was a significant increase of expression in
the PTC tissues compared to the benign thyroid tumors (8.9-fold,
p = 0.019 and 38.4-fold, p = 0.014, respectively).
We also studied the distribution and localization of integrins
ITGA2 and ITGB3 in the thyroid tissues by IHC. In normal thyroid
tissues ITGA2 and ITGB3 were located mainly in the follicular
membrane. In the PTC tissue samples another location of the
integrins was registered: ITGA2 was located mainly in the
papillary structures, whereas ITGB3 was seen both at the basal
and apical surfaces of thyrocytes. Follicular adenomawas charac-
terized by a uniform distribution of both ITGA2 and ITGB3.
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